Ryosuke Hashizume1, Hidejiro Kawahara2, Masaichi Ogawa3, Katsuhito Suwa4, Ken Eto5, Katsuhiko Yanaga5. 1. Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan hashihide@jikei.ac.jp. 2. Department of Surgery, Kashiwa Hospital, The Jikei University School of Medicine, Chiba, Japan. 3. Department of Surgery, Katsushika Medical Center, The Jikei University School of Medicine, Tokyo, Japan. 4. Department of Surgery, the Third Hospital, The Jikei University School of Medicine, Tokyo, Japan. 5. Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Abstract
BACKGROUND/AIM: To evaluate whether the serum levels of CEA or CA19-9 concentration is a useful predictor of survival in patients with metastatic colon cancer (mCC). PATIENTS AND METHODS: Between 2012 and 2015, 113 patients with mCC who underwent chemotherapy according to the Japanese Colorectal Cancer Treatment Guidelines at four Jikei University Hospitals were enrolled in this study. The two serum tumor makers, CEA and CA19-9 were measured before first-line chemotherapy and at four months thereafter. RESULTS: Serum CA19-9 concentration at four months after first-line chemotherapy (p=0.003, HR=3.761) and first-line chemotherapy including oxaliplatin (p=0.038, HR=0.312) were independent predictors of survival in patients with mCC. By excluding the transverse colon, only serum CA19-9 concentration at four months after first-line chemotherapy (p=0.005, HR=3.660) was identified as the predictor of survival. CONCLUSION: Serum CA19-9 concentration after first-line chemotherapy seems to be a useful predictor of survival in patients with mCC. Copyright
BACKGROUND/AIM: To evaluate whether the serum levels of CEA or CA19-9 concentration is a useful predictor of survival in patients with metastatic colon cancer (mCC). PATIENTS AND METHODS: Between 2012 and 2015, 113 patients with mCC who underwent chemotherapy according to the Japanese Colorectal Cancer Treatment Guidelines at four Jikei University Hospitals were enrolled in this study. The two serum tumor makers, CEA and CA19-9 were measured before first-line chemotherapy and at four months thereafter. RESULTS: Serum CA19-9 concentration at four months after first-line chemotherapy (p=0.003, HR=3.761) and first-line chemotherapy including oxaliplatin (p=0.038, HR=0.312) were independent predictors of survival in patients with mCC. By excluding the transverse colon, only serum CA19-9 concentration at four months after first-line chemotherapy (p=0.005, HR=3.660) was identified as the predictor of survival. CONCLUSION: Serum CA19-9 concentration after first-line chemotherapy seems to be a useful predictor of survival in patients with mCC. Copyright
Authors: J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier Journal: Lancet Date: 2000-03-25 Impact factor: 79.321
Authors: Johanna Louhimo; Monika Carpelan-Holmström; Henrik Alfthan; Ulf-Håkan Stenman; Heikki J Järvinen; Caj Haglund Journal: Int J Cancer Date: 2002-10-20 Impact factor: 7.396
Authors: Sabine Venderbosch; Iris D Nagtegaal; Tim S Maughan; Christopher G Smith; Jeremy P Cheadle; David Fisher; Richard Kaplan; Philip Quirke; Matthew T Seymour; Susan D Richman; Gerrit A Meijer; Bauke Ylstra; Danielle A M Heideman; Anton F J de Haan; Cornelis J A Punt; Miriam Koopman Journal: Clin Cancer Res Date: 2014-08-19 Impact factor: 12.531